Earnings ·
Design Therapeutics reports Q3 net loss of $20.3M on $22.2M in expenses
DSGNDesign Therapeutics, Inc.
Design Therapeutics reported a net loss of $20.3 million for the third quarter ended September 30, 2026, compared to a loss of $17.0 million in the prior-year period. Research and development expenses increased to $16.9 million from $14.6 million, while general and administrative costs rose to $5.3 million from $4.7 million. The company ended the quarter with $208.6 million in cash, cash equivalents, and investment securities. Regarding clinical progress, Design Therapeutics expects to provide an update on registrational plans for its DT-216P2 program in Friedreich ataxia during Q4 2026, with data expected in Q1 2027. The company is a clinical-stage biotechnology firm developing gene-targeted therapies for degenerative genetic diseases.